Wedbush initiated coverage on Epizyme (NASDAQ: EPZM) with an Outperform rating and a price target of $37.00.

"Advances in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE